• Royalty Pharma reiterated full-year 2026 Portfolio Receipts guidance of USD 3.28 billion to USD 3.43 billion, excluding transactions announced after Feb. 11, 2026.
• Guidance assumes Royalty Receipts growth of 3% to 8%.
• Milestones and other contractual receipts expected at about USD 60 million in 2026 versus USD 128 million in 2025.
• Operating and professional cost payments forecast at 5.5% to 6.5% of Portfolio Receipts.
• Interest paid outlook set at USD 350 million to USD 360 million, with about USD 175 million in each of first quarter and third quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.